Data completeness
0/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LERITINE (anileridine phosphate) is an injectable opioid analgesic in pre-launch stage under NDA review by Merck & Co. The mechanism of action and specific therapeutic indications are not yet publicly disclosed. This product represents a synthetic opioid development program potentially targeting acute or chronic pain management via parenteral administration.
Pre-Launch
Pre-launch stage means commercial infrastructure is being built; career opportunities exist in launch planning, market access, and regulatory affairs teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LERITINE offers entry into a product at the critical pre-launch phase under a major sponsor (Merck). Career advancement potential is high if approval is granted, with opportunities spanning commercial launch, medical education, and market access strategy.
Brand ManagerRegulatory Affairs Specialist
Worked on LERITINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.